Dashboard Tools Market News Investing Ideas Pricing About Us
Sign Up
Log in
D

Day One Biopharmaceuticals Inc
NASDAQ:DAWN

Watchlist Manager
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Watchlist
Price: 11.54 USD 3.41% Market Closed
Market Cap: $1.2B
Write Note Create Alert Ask AI
Price Target
Loading...
Revenue
Loading...
Operating Income
Loading...
Net Income
Loading...

Wall Street
Price Targets

DAWN Price Targets Summary
Day One Biopharmaceuticals Inc

Wall Street analysts forecast DAWN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DAWN is 24.03 USD with a low forecast of 16.16 USD and a high forecast of 35.7 USD.

DAWN Lowest Forecast
Wall Street Target
16.16 USD
40% Upside
DAWN Average Forecast
Wall Street Target
24.03 USD
108% Upside
DAWN Highest Forecast
Wall Street Target
35.7 USD
209% Upside
Lowest
Price Target
16.16 USD
40% Upside
Average
Price Target
24.03 USD
108% Upside
Highest
Price Target
35.7 USD
209% Upside
Day One Biopharmaceuticals Inc Competitors:
Price Targets
BCBP
BCB Bancorp Inc
26% Upside
TENB
Tenable Holdings Inc
69% Upside
HOTH
Hoth Therapeutics Inc
404% Upside
CALM
Cal-Maine Foods Inc
7% Upside
BCBP
BCB Bancorp Inc
26% Upside
TENB
Tenable Holdings Inc
69% Upside
HOTH
Hoth Therapeutics Inc
404% Upside
CALM
Cal-Maine Foods Inc
7% Upside
UFPT
UFP Technologies Inc
15% Upside

Revenue
Forecast

N/A
Past Growth
36% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
36% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of Day One Biopharmaceuticals Inc's revenue for the next 4 years is 36%.

What are analyst estimates?

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
0%
Average Miss

What are analyst estimates?

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-30%
Average Miss

What are analyst estimates?

See Also

Summary
DAWN intrinsic value, competitors valuation, and company profile.
DCF Valuation
DAWN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DAWN stock valuation using valuation multiples.
Wall Street Estimates
DAWN price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DAWN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DAWN's stock price target?
Price Target
24.03 USD

According to Wall Street analysts, the average 1-year price target for DAWN is 24.03 USD with a low forecast of 16.16 USD and a high forecast of 35.7 USD.

What is Day One Biopharmaceuticals Inc's Revenue forecast?
Projected CAGR
36%

The compound annual growth rate of Day One Biopharmaceuticals Inc's revenue for the next 4 years is 36%.

Back to Top
ALPHA SPREAD
Follow us
Join more than 314,500+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.